Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Icosavax, Inc. stock logo
ICVX
Icosavax
$15.31
$15.32
$4.75
$16.10
$766.88M1.281.22 million shsN/A
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
$4.71
-3.1%
$5.85
$3.49
$8.35
$302.46M1.29154,257 shs121,649 shs
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
$4.95
-2.2%
$4.90
$2.13
$7.37
$322.89M1.1759,689 shs22,899 shs
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
$4.22
-3.7%
$5.15
$1.66
$8.09
$331.35M2.6551,989 shs384,556 shs
Vaxart, Inc. stock logo
VXRT
Vaxart
$0.66
-7.1%
$1.13
$0.53
$1.59
$116.43M0.441.96 million shs1.92 million shs
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Icosavax, Inc. stock logo
ICVX
Icosavax
0.00%0.00%0.00%+0.13%+160.37%
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
-3.09%-5.99%-23.54%-30.22%-12.45%
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
-2.17%+3.13%+0.61%+1.02%+6.22%
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
-3.65%-1.63%-12.63%+0.72%-10.50%
Vaxart, Inc. stock logo
VXRT
Vaxart
-7.23%-21.83%-46.03%-24.67%-8.25%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Icosavax, Inc. stock logo
ICVX
Icosavax
1.1693 of 5 stars
3.20.00.00.00.04.20.0
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
4.1544 of 5 stars
3.53.00.04.81.91.70.6
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
2.2662 of 5 stars
3.55.00.00.01.70.00.6
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
1.5668 of 5 stars
3.51.00.00.00.05.00.0
Vaxart, Inc. stock logo
VXRT
Vaxart
1.2026 of 5 stars
3.51.00.00.02.60.00.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Icosavax, Inc. stock logo
ICVX
Icosavax
2.33
Hold$26.5073.09% Upside
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
3.00
Buy$25.67444.94% Upside
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
3.00
Buy$8.0061.62% Upside
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
3.00
Buy$15.40264.93% Upside
Vaxart, Inc. stock logo
VXRT
Vaxart
3.00
Buy$3.00355.65% Upside

Current Analyst Ratings

Latest VXRT, TNYA, MGTX, SOPH, and ICVX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/21/2024
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
3/20/2024
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$19.00 ➝ $18.00
3/19/2024
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$18.00
3/15/2024
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$11.00
3/6/2024
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$7.00 ➝ $8.00
3/6/2024
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$8.00
1/31/2024
Vaxart, Inc. stock logo
VXRT
Vaxart
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$2.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Icosavax, Inc. stock logo
ICVX
Icosavax
$580K1,322.20N/AN/A$5.47 per share2.80
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
$14.02M21.58N/AN/A$2.17 per share2.17
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
$62.37M5.18N/AN/A$3.16 per share1.57
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
N/AN/AN/AN/A$2.05 per shareN/A
Vaxart, Inc. stock logo
VXRT
Vaxart
$7.38M15.78N/AN/A$0.38 per share1.73

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Icosavax, Inc. stock logo
ICVX
Icosavax
-$91.76M-$2.22N/AN/AN/AN/A-43.06%-39.53%N/A
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
-$84.03M-$1.47N/A5.23N/A-599.47%-114.33%-42.56%5/9/2024 (Estimated)
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
-$78.98M-$1.22N/AN/AN/A-126.63%-47.40%-36.43%5/7/2024 (Confirmed)
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
-$124.08M-$1.67N/AN/AN/AN/A-69.94%-59.80%5/8/2024 (Estimated)
Vaxart, Inc. stock logo
VXRT
Vaxart
-$82.46M-$0.58N/AN/AN/A-1,117.56%-108.45%-73.31%5/2/2024 (Estimated)

Latest VXRT, TNYA, MGTX, SOPH, and ICVX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
-$0.28N/A+$0.28N/AN/AN/A  
3/18/2024Q4 2023
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
-$0.45-$0.40+$0.05-$0.40N/AN/A
3/14/2024Q4 2023
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
-$0.46-$0.47-$0.01-$1.36$10.13 million$2.04 million
3/14/2024Q4 2023
Vaxart, Inc. stock logo
VXRT
Vaxart
-$0.15-$0.12+$0.03-$0.12$0.45 million$3.25 million    
3/5/202412/31/2023
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
-$0.25-$0.37-$0.12-$0.37$16.78 million$17.05 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Icosavax, Inc. stock logo
ICVX
Icosavax
N/AN/AN/AN/AN/A
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
N/AN/AN/AN/AN/A
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
N/AN/AN/AN/AN/A
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
N/AN/AN/AN/AN/A
Vaxart, Inc. stock logo
VXRT
Vaxart
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Icosavax, Inc. stock logo
ICVX
Icosavax
N/A
18.06
18.06
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
0.62
2.38
2.38
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
N/A
4.16
3.97
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
N/A
4.91
4.91
Vaxart, Inc. stock logo
VXRT
Vaxart
N/A
3.32
3.32

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Icosavax, Inc. stock logo
ICVX
Icosavax
92.59%
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
67.48%
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
31.59%
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
90.54%
Vaxart, Inc. stock logo
VXRT
Vaxart
18.05%

Insider Ownership

CompanyInsider Ownership
Icosavax, Inc. stock logo
ICVX
Icosavax
30.59%
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
9.70%
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
4.88%
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
33.83%
Vaxart, Inc. stock logo
VXRT
Vaxart
3.00%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Icosavax, Inc. stock logo
ICVX
Icosavax
6050.09 million34.77 millionOptionable
MeiraGTx Holdings plc stock logo
MGTX
MeiraGTx
41964.22 million57.99 millionOptionable
SOPHiA GENETICS SA stock logo
SOPH
SOPHiA GENETICS
43065.23 million62.05 millionNot Optionable
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
14078.52 million51.96 millionOptionable
Vaxart, Inc. stock logo
VXRT
Vaxart
109176.84 million171.53 millionOptionable

VXRT, TNYA, MGTX, SOPH, and ICVX Headlines

SourceHeadline
Vaxart (NASDAQ:VXRT) Shares Cross Below 200-Day Moving Average of $0.88Vaxart (NASDAQ:VXRT) Shares Cross Below 200-Day Moving Average of $0.88
marketbeat.com - April 26 at 4:00 AM
Vaxart (NASDAQ:VXRT) Stock Passes Below 200 Day Moving Average of $0.88Vaxart (NASDAQ:VXRT) Stock Passes Below 200 Day Moving Average of $0.88
americanbankingnews.com - April 18 at 3:24 AM
Election Year Encore: Can 2020s Top 7 Stock Winners Repeat Their Performance in 2024?Election Year Encore: Can 2020's Top 7 Stock Winners Repeat Their Performance in 2024?
investorplace.com - April 9 at 4:30 PM
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
globenewswire.com - March 27 at 8:00 AM
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com - March 20 at 8:00 AM
Estimating The Intrinsic Value Of Vaxart, Inc. (NASDAQ:VXRT)Estimating The Intrinsic Value Of Vaxart, Inc. (NASDAQ:VXRT)
finance.yahoo.com - March 17 at 3:11 PM
Vaxart, Inc. (NASDAQ:VXRT) Q4 2023 Earnings Call TranscriptVaxart, Inc. (NASDAQ:VXRT) Q4 2023 Earnings Call Transcript
finance.yahoo.com - March 15 at 3:15 PM
VXRT Stock Earnings: Vaxart Beats EPS, Beats Revenue for Q4 2023VXRT Stock Earnings: Vaxart Beats EPS, Beats Revenue for Q4 2023
investorplace.com - March 14 at 10:04 PM
Vaxart Inc (VXRT) Reports Full Year 2023 Financial ResultsVaxart Inc (VXRT) Reports Full Year 2023 Financial Results
finance.yahoo.com - March 14 at 7:13 PM
Vaxart Provides Business Update and Reports Full Year 2023 Financial ResultsVaxart Provides Business Update and Reports Full Year 2023 Financial Results
globenewswire.com - March 14 at 4:01 PM
Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14
globenewswire.com - March 7 at 8:00 AM
Vaxart Names Steven Lo President, Chief ExecutiveVaxart Names Steven Lo President, Chief Executive
marketwatch.com - March 6 at 6:06 PM
Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and DirectorVaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director
globenewswire.com - March 6 at 8:00 AM
VAXART, INC. (VXRT) is a Great Momentum Stock: Should You Buy?VAXART, INC. (VXRT) is a Great Momentum Stock: Should You Buy?
zacks.com - February 26 at 1:00 PM
5 Top-Ranked Stocks That Have More Than Doubled Year to Date5 Top-Ranked Stocks That Have More Than Doubled Year to Date
zacks.com - February 23 at 10:11 AM
VAXART, INC. (VXRT) Now Trades Above Golden Cross: Time to Buy?VAXART, INC. (VXRT) Now Trades Above Golden Cross: Time to Buy?
finance.yahoo.com - February 20 at 3:15 PM
VAXART, INC. (VXRT) Now Trades Above Golden Cross: Time to Buy?VAXART, INC. (VXRT) Now Trades Above Golden Cross: Time to Buy?
zacks.com - February 20 at 10:56 AM
Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 ChallengeVaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge
finance.yahoo.com - February 5 at 12:43 PM
Vaxart CEO Resigns; Biotech Raises $10 Million in Stock SaleVaxart CEO Resigns; Biotech Raises $10 Million in Stock Sale
marketwatch.com - January 16 at 10:39 AM
Vaxart, Inc. Announces Management ChangeVaxart, Inc. Announces Management Change
finance.yahoo.com - January 16 at 10:39 AM
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital ManagementVaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management
finance.yahoo.com - January 16 at 10:39 AM
Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating MothersVaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers
finance.yahoo.com - December 21 at 9:40 AM
Heres Why Vaxart (NASDAQ:VXRT) Must Use Its Cash WiselyHere's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely
finance.yahoo.com - November 7 at 10:09 AM
Vaxart, Inc. (NASDAQ:VXRT) Q3 2023 Earnings Call TranscriptVaxart, Inc. (NASDAQ:VXRT) Q3 2023 Earnings Call Transcript
finance.yahoo.com - November 3 at 1:45 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Icosavax logo

Icosavax

NASDAQ:ICVX
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.
MeiraGTx logo

MeiraGTx

NASDAQ:MGTX
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.
SOPHiA GENETICS logo

SOPHiA GENETICS

NASDAQ:SOPH
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.
Tenaya Therapeutics logo

Tenaya Therapeutics

NASDAQ:TNYA
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Vaxart logo

Vaxart

NASDAQ:VXRT
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical dysplasia. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.